title: Impact of antiretroviral therapy on quality of life in HIV-infected Southeast Asian children in the PREDICT study.
abstract: Quality of life (QOL) is an important antiretroviral treatment (ART) outcome. We compared QOL among 299 Thai and Cambodian children ages 1-12 years-old, CD4 15-24% randomized to early (ART at week 0, N=149) versus deferred groups (ART when at CD4 <15%, N=150) and also compared with QOL data from age-matched healthy controls (N=275). Primary caregivers completed PACTG QOL questionnaires at week 0 and every 24 weeks until 144 weeks. Children were enrolled during March 2006 to September 2008. Mean (SD) age of children was 6.3 (2.8) years, 58% were female, 60% were Thai, %CDC N:A:B:C was 2:62:36:0%. During 144 weeks, all children in the early-group and 69 (46%) of deferred-group children started ART. There was no significant difference of QOL scores between treatment groups at baseline (all p>0.05) and at week 144 (all p>0.05). By multivariate analysis, the early-group had higher QOL score changes in five domains, including health perception (p=0.04), physical resilience (p=0.02), psychosocial well-being (p=0.04), social and role functioning (p<0.01), and symptoms (p=0.01) compared to the deferred group. QOL of HIV-infected children in both groups were lower than healthy control in all 7 domains at baseline (all p<0.05) and 5 of 7 domains at weeks 144 (p<0.01). In conclusion, no significant difference of QOL scores between treatment groups. Early ART commencement associated with greater increase of QOL scores over 144 weeks. QOL scores in HIV-infected children were lower than healthy controls.
authors.affiliation: 1 HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Center , Bangkok, Thailand .
authors.forename: Torsak
authors.initials: T
authors.lastname: Bunupuradah
authors.forename: Pope
authors.initials: P
authors.lastname: Kosalaraksa
authors.forename: Ung
authors.initials: U
authors.lastname: Vibol
authors.forename: Rawiwan
authors.initials: R
authors.lastname: Hansudewechakul
authors.forename: Jiratchaya
authors.initials: J
authors.lastname: Sophonphan
authors.forename: Suparat
authors.initials: S
authors.lastname: Kanjanavanit
authors.forename: Chaiwat
authors.initials: C
authors.lastname: Ngampiyaskul
authors.forename: Jurai
authors.initials: J
authors.lastname: Wongsawat
authors.forename: Wicharn
authors.initials: W
authors.lastname: Luesomboon
authors.forename: Saphonn
authors.initials: S
authors.lastname: Vonthanak
authors.forename: Jintanat
authors.initials: J
authors.lastname: Ananworanich
authors.forename: Kiat
authors.initials: K
authors.lastname: Ruxrungtham
authors.forename: Thanyawee
authors.initials: T
authors.lastname: Puthanakit
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002160:Cambodia; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000523:psychology* / Q000821:virology; D006801:Humans; D007223:Infant; D008297:Male; D015999:Multivariate Analysis; D011788:Quality of Life; D011795:Surveys and Questionnaires; D013785:Thailand; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents